+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 19Nov
    Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome

     

  • 29Oct
    Newron Initiates Outreach on First Global Rett Syndrome Burden of Illness Survey in Collaboration with the Rett Community

  • 20Sep
    Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson’s disease in Japan

  • 12Sep
    Newron reports half-year 2019 results

     

  • 10Jul
    Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada

     

  • 28Jun
    Newron Receives First Tranche from Financing Agreement with European Investment Bank (EIB)

     

View All

Newron share price

Events

  • 26Nov
    German Equity Forum 2019

    November, 25-27, 2019 -Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt, Germany

  • 20Nov
    10th Annual Jefferies 2019 London Healthcare Conference

    November 20-21, 2019 - the Waldorf Hilton, London, UK

  • 18Sep
    Investora Zürich 2019

    September 18-19, 2019 - Samsung Hall, Dübendorf, Switzerland

View Event Calendar